Meyer F - Search Results

1

Deletions of the INK4A gene in superficial bladder tumors. Association with recurrence.

Orlow I, LaRue H, Osman I, Lacombe L, Moore L, Rabbani F, Meyer F, Fradet Y, Cordon-Cardo C. Orlow I, et al. Among authors: meyer f. Am J Pathol. 1999 Jul;155(1):105-13. doi: 10.1016/S0002-9440(10)65105-X. Am J Pathol. 1999. PMID: 10393843 Free PMC article.

2

Prognostic value of the proliferative index determined by Ki-67 immunostaining in superficial bladder tumors.

Pfister C, Lacombe L, Vezina MC, Moore L, Larue H, Têtu B, Meyer F, Fradet Y. Pfister C, et al. Among authors: meyer f. Hum Pathol. 1999 Nov;30(11):1350-5. doi: 10.1016/s0046-8177(99)90067-9. Hum Pathol. 1999. PMID: 10571516

3

P53 point mutations in initial superficial bladder cancer occur only in tumors from current or recent cigarette smokers.

LaRue H, Allard P, Simoneau M, Normand C, Pfister C, Moore L, Meyer F, Têtu B, Fradet Y. LaRue H, et al. Among authors: meyer f. Carcinogenesis. 2000 Jan;21(1):101-6. doi: 10.1093/carcin/21.1.101. Carcinogenesis. 2000. PMID: 10607740

4

Predictive value of cell cycle markers p53, MDM2, p21, and Ki-67 in superficial bladder tumor recurrence.

Pfister C, Moore L, Allard P, Larue H, Lacombe L, Têtu B, Meyer F, Fradet Y. Pfister C, et al. Among authors: meyer f. Clin Cancer Res. 1999 Dec;5(12):4079-84. Clin Cancer Res. 1999. PMID: 10632343

5

Tumorigenic pathways in low-stage bladder cancer based on p53, MDM2 and p21 phenotypes.

Pfister C, Larue H, Moore L, Lacombe L, Veilleux C, Tetu B, Meyer F, Fradet Y. Pfister C, et al. Among authors: meyer f. Int J Cancer. 2000 Jan 20;89(1):100-4. Int J Cancer. 2000. PMID: 10719738

6

Chromosome 9 deletions and recurrence of superficial bladder cancer: identification of four regions of prognostic interest.

Simoneau M, LaRue H, Aboulkassim TO, Meyer F, Moore L, Fradet Y. Simoneau M, et al. Among authors: meyer f. Oncogene. 2000 Dec 14;19(54):6317-23. doi: 10.1038/sj.onc.1204022. Oncogene. 2000. PMID: 11175346

7

Matrix metalloproteinase 9 is associated with Gleason score in prostate cancer but not with prognosis.

Trudel D, Fradet Y, Meyer F, Têtu B. Trudel D, et al. Among authors: meyer f. Hum Pathol. 2010 Dec;41(12):1694-701. doi: 10.1016/j.humpath.2010.05.001. Epub 2010 Sep 9. Hum Pathol. 2010. PMID: 20825973

8

Downward trend in prostate cancer mortality in Quebec and Canada.

Meyer F, Moore L, Bairati I, Fradet Y. Meyer F, et al. J Urol. 1999 Apr;161(4):1189-91. J Urol. 1999. PMID: 10081867

9

Neoadjuvant hormonal therapy before radical prostatectomy and risk of prostate specific antigen failure.

Meyer F, Moore L, Bairati I, Lacombe L, Têtu B, Fradet Y. Meyer F, et al. J Urol. 1999 Dec;162(6):2024-8. doi: 10.1016/S0022-5347(05)68092-5. J Urol. 1999. PMID: 10569561 Review.

10

Maintenance bacillus Calmette-Guérin in high-risk nonmuscle-invasive bladder cancer: how much is enough?

Decobert M, LaRue H, Harel F, Meyer F, Fradet Y, Lacombe L. Decobert M, et al. Among authors: meyer f. Cancer. 2008 Aug 15;113(4):710-6. doi: 10.1002/cncr.23627. Cancer. 2008. PMID: 18543328 Free article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

2,820 results

Search Page

Filters